RELMADA THERAPEUTICS INC (RLMD)

US75955J4022 - Common Stock

0.4701  +0.02 (+4.44%)

After market: 0.46 -0.01 (-2.15%)

Free users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

TTM
(2024-9-30)
2023
(2023-12-31)
2022
(2022-12-31)
2021
(2021-12-31)
2020
(2020-12-31)
Revenue
0.000.000.000.000.00
Operating Expenses
91.64M103.70M161.25M125.70M60.84M
Research and Development
49.93M54.81M113.32M90.62M35.97M
Selling, General, and Administrative Expenses
41.72M48.89M47.93M35.08M24.87M
Operating Income
-91.64M-103.70M-161.25M-125.70M-60.84M
Interest Income/Expense
5.16M4.91M-2.15M-50.00K1.38M
Other Income/Expense
N/A0.006.35MN/AN/A
Non Recurring Items
N/AN/AN/AN/AN/A
Income Before Taxes
-86.49M-98.79M-157.04M-125.75M-59.46M
Income Tax
N/AN/AN/AN/AN/A
Net Income
-86.49M-98.79M-157.04M-125.75M-59.46M
EBITDA
N/AN/AN/AN/AN/A
 
Per Share Data
EPS Diluted Total Ops
-2.87-3.28-5.30-7.16-3.81
Non GAAP EPS
-2.87-3.28-5.45-7.14N/A
 
Statistics

All data in USD

Charts